Source comparison
Does Sermorelin Help Anti-Aging Research? Comparison of Research Models
Sermorelin (GHRH analogue) Stimulates pituitary GH release via GHRH receptor agonism 25–35% increase within physiological range Fully preserved. Somatostatin and IGF-1 modulate secretion <5% (mild injection site reactions) 9/10. Ideal for studying endogenous a
This comparison does not assign a generated winner or score.
- Sermorelin (GHRH analogue)
- Stimulates pituitary GH release via GHRH receptor agonism
- 25–35% increase within physiological range
- Fully preserved. Somatostatin and IGF-1 modulate secretion
- <5% (mild injection site reactions)
- 9/10. Ideal for studying endogenous axis restoration
- Recombinant human GH (rhGH)
- Direct GH receptor agonism (bypasses pituitary)
- 60–120% increase, often supraphysiological
- Suppressed. Negative feedback shuts down endogenous production
- 15–25% (arthralgias, edema, insulin resistance)
- 6/10. Useful for supraphysiological studies but confounds natural regulation
- GH secretagogues (ghrelin mimetics)
- Activates ghrelin receptors on pituitary and hypothalamus
- 40–80% increase, highly variable
- Partially preserved. Depends on receptor desensitization
- 8–12% (increased appetite, transient hyperglycemia)
- 7/10. Good for studying ghrelin-GH crosstalk but less consistent
- Placebo (saline injection)
- No active mechanism
- No change from baseline
- Unaffected
- <2% (nocebo effects)
- 5/10. Necessary control but no therapeutic signal